{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:09Z","timestamp":1758845889548,"version":"3.44.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["522004005"],"award-info":[{"award-number":["522004005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatitis A (hepA) vaccination generates long-lasting protection against hepA in healthy adults. However, the duration of protection in immunocompromised patients (ICPs), such as people living with HIV (PLWH) and patients on immunosuppressive therapy, is uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This 3-year follow-up study of a prospective cohort assessed hepA antibodies in PLWH, patients on immunosuppressive therapy, and controls after completing a full hepA vaccination series. Three years later (Y3), serum samples were collected in 88\/150 (59%) of original participants. The primary outcome was the seroprotection rate (SPR) at Y3, defined as the proportion of participants with hepA antibodies \u226520 mIU\/mL. Secondary outcomes included seroreversion rates, defined as the proportion of those unprotected at Y3, among those initially protected after the primary vaccination schedule, and geometric mean concentrations (GMCs) at Y3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At Y3, SPRs were 87% (20\/23) in PLWH, 90% (26\/29) in patients on immunosuppressive monotherapy, 65% (13\/20) in patients on immunosuppressive combination therapy, and 100% (16\/16) in controls. Seroreversion rates were 13% (3\/23) in PLWH, 10% (3\/29) in patients on immunosuppressive monotherapy, 21% (4\/19) in patients on immunosuppressive combination therapy, and 0% (0\/16) in controls. GMCs in ICPs (41.13\u201370.75\u2005mIU\/mL) were significantly lower compared to controls (175.65\u2005mIU\/mL) (P-value = .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Three years postvaccination, most ICPs remained seroprotected, but SPRs and GMCs were lower than in healthy controls, particularly in patients on combination immunosuppressive therapy. However, it remains uncertain if booster doses are necessary among those who seroreverted, as long-term protection may persist through formed cellular memory.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf457","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:59:26Z","timestamp":1758311966000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term Immunogenicity of Hepatitis A Vaccination in Adults Receiving Immunosuppressive Therapy and Adults Living With HIV: Three-year Follow-up of a Prospective Cohort Study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-8130","authenticated-orcid":false,"given":"Jenny L","family":"Schnyder","sequence":"first","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-5455","authenticated-orcid":false,"given":"Hannah M","family":"Garcia Garrido","sequence":"additional","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-2139","authenticated-orcid":false,"given":"Irma","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes M","family":"Harskamp","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-7754","authenticated-orcid":false,"given":"Neeltje A","family":"Kootstra","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-1099","authenticated-orcid":false,"given":"Martin P","family":"Grobusch","sequence":"additional","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-6217","authenticated-orcid":false,"given":"Abraham","family":"Goorhuis","sequence":"additional","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"author":"World Health Organization","key":"2025092508531716800_ofaf457-B1"},{"key":"2025092508531716800_ofaf457-B2","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.lanepe.2020.100001","article-title":"Travel-related infections presenting in Europe: a 20-year analysis of EuroTravNet surveillance data","volume":"1","author":"Grobusch","year":"2021","journal-title":"Lancet Reg Health Eur"},{"author":"National Institute for Public Health and the Environment","key":"2025092508531716800_ofaf457-B3"},{"key":"2025092508531716800_ofaf457-B4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/338152","article-title":"Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection","volume":"34","author":"Ida","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2025092508531716800_ofaf457-B5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/517144","article-title":"Hepatitis A in human immunodeficiency virus-infected patients","volume":"27","author":"Wallace","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2025092508531716800_ofaf457-B6","first-page":"493","article-title":"WHO position paper on hepatitis A vaccines\u2014October 2022","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"volume-title":"WHO Immunological basis for immunization series, module 18: hepatitis A update","year":"2019","author":"World Health Organization","key":"2025092508531716800_ofaf457-B7"},{"key":"2025092508531716800_ofaf457-B8","doi-asserted-by":"crossref","first-page":"taae125","DOI":"10.1093\/jtm\/taae125","article-title":"Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study","volume":"32","author":"Schnyder","year":"2025","journal-title":"J Travel Med"},{"key":"2025092508531716800_ofaf457-B9","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.tmaid.2019.101479","article-title":"Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: a systematic review and meta-analysis","volume":"32","author":"Garcia Garrido","year":"2019","journal-title":"Travel Med Infect Dis"},{"key":"2025092508531716800_ofaf457-B10","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/infdis\/jir180","article-title":"Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults","volume":"203","author":"Crum-Cianflone","year":"2011","journal-title":"J Infect Dis"},{"key":"2025092508531716800_ofaf457-B11","first-page":"606","article-title":"Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in human immunodeficiency virus\u2013positive adults on antiretroviral therapy","volume":"215","author":"Cheng","year":"2017","journal-title":"J Infect Dis"},{"key":"2025092508531716800_ofaf457-B12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.rpped.2014.09.005","article-title":"Persistence of hepatitis A virus antibodies after primary immunization and response to revaccination in children and adolescents with perinatal HIV exposure","volume":"33","author":"Gouv\u00eaa","year":"2015","journal-title":"Rev Paul Pediatr"},{"key":"2025092508531716800_ofaf457-B13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2025092508531716800_ofaf457-B14","doi-asserted-by":"crossref","first-page":"2239946","DOI":"10.1080\/22221751.2023.2239946","article-title":"Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study","volume":"12","author":"Lin","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"2025092508531716800_ofaf457-B15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/hep.30495","article-title":"Early seroreversion after 2 doses of hepatitis A vaccination in human immunodeficiency virus\u2013positive patients: incidence and associated factors","volume":"70","author":"Huang","year":"2019","journal-title":"Hepatology"},{"key":"2025092508531716800_ofaf457-B16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tmaid.2014.01.005","article-title":"Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"2025092508531716800_ofaf457-B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41541-024-00874-4","article-title":"Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies","volume":"9","author":"Hou","year":"2024","journal-title":"NPJ Vaccines"},{"volume-title":"IBM SPSS statistics for windows, version 28.0","year":"2021","author":"IBM Corp","key":"2025092508531716800_ofaf457-B18"},{"volume-title":"Graphpad prism, version 9.0.0 for windows","year":"2020","author":"GraphPad Software Inc","key":"2025092508531716800_ofaf457-B19"},{"key":"2025092508531716800_ofaf457-B20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00007890-200102150-00023","article-title":"Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients","volume":"71","author":"G\u00fcnther","year":"2001","journal-title":"Transplantation"},{"key":"2025092508531716800_ofaf457-B21","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/0264-410X(92)90572-2","article-title":"Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees","volume":"10 Suppl 1","author":"Purcell","year":"1992","journal-title":"Vaccine"},{"key":"2025092508531716800_ofaf457-B22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1994.03510410040030","article-title":"Protection against hepatitis A by an inactivated vaccine","volume":"271","author":"Innis","year":"1994","journal-title":"JAMA"},{"key":"2025092508531716800_ofaf457-B23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199208133270702","article-title":"A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children","volume":"327","author":"Werzberger","year":"1992","journal-title":"N Engl J Med"},{"key":"2025092508531716800_ofaf457-B24","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.vaccine.2015.06.099","article-title":"A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection","volume":"33","author":"Melgaco","year":"2015","journal-title":"Vaccine"},{"year":"","author":"Schnyder","key":"2025092508531716800_ofaf457-B25"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf457\/64267991\/ofaf457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf457\/64267991\/ofaf457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:53:28Z","timestamp":1758804808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf457\/8254019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf457","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]},"article-number":"ofaf457"}}